Lung cancer is the leading cause of cancer mortality, and radiotherapy plays a key role in
both curative and palliative treatments for this disease. Recent advances include stereotactic …

Radiotherapy is an important modality used for the treatment of lung cancer. Seventy‐seven
percent of all patients with lung cancer have an evidence‐based indication for radiotherapy …

The use of stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung
cancer is growing rapidly, particularly since it has become the recommended therapy for …

Background and purpose To assess the efficacy of stereotactic ablative radiotherapy (SABR)
for the treatment of non-small cell lung cancer (NSCLC) through a systematic review of all …

Stereotactic ablative radiotherapy (SABR) is a technique that has rapidly entered routine
care for early-stage peripheral non-small cell lung cancer in many countries in the last …

Background Lung cancer is the second most diagnosed cancer and the leading cause of
cancer-related mortality in Canada. Surgical resection is the treatment of choice for patients …

Background and purpose We report our outcomes for patients with NSCLC treated with
SABR to 70 Gy in 10 fractions and propose indications for this regimen as well as new dose …

Stereotactic body radiotherapy (SBRT) represents a consolidated treatment option for
patients with medically inoperable early stage non-small cell lung cancer (NSCLC). The …

Recent advances in systemic cytotoxic and molecularly targeted therapies coupled with
technologic strides in radiotherapy have the potential to improve outcomes for patients with …

BACKGROUND AND PURPOSE: Stereotactic ablative radiotherapy (SABR) has improved
the survival for medically inoperable patients with peripheral early-stage non-small cell lung …